Generic Name and Formulations:
Alprostadil 5mcg, 10mcg, 20mcg, 40mcg; per vial; lyophilized pwd for intracavernous inj after reconstitution; contains benzyl alcohol.
Indications for CAVERJECT:
Treatment of erectile dysfunction. Adjunct to other diagnostic tests in the diagnosis of erectile dysfunction.
Inject into the dorso-lateral aspect of the proximal third of penis, avoid visible veins; rotate inj side and site. Determine optimum dose in office. If no response, may give 2nd dose after 1hr; if partial response occurs, wait 24hrs before next dose. Vasculogenic, psychogenic, or mixed etiology: initially 2.5mcg; if partial response, may give 2nd dose of 5mcg; may increase in increments of 5–10mcg until desired response. If no response to 1st dose, may give 2nd dose of 7.5mcg within 1hr; may increase in increments of 5–10mcg until desired response. Neurogenic etiology: initially 1.25mcg; may give 2nd dose of 2.5mcg, and 3rd dose of 5mcg; may increase in increments of 5mcg until desired response. Usual max: 60mcg and 3 inj/week; allow at least 24hrs between doses. Reduce dose if erection lasts over 1hr. Adjunct in diagnosis: see full labeling.
Not indicated; see Contraindications.
Predisposition to priapism. Anatomical penile deformation. Penile implants. Patients for whom sexual activity is inadvisable or contraindicated. Women. Children. Newborns.
Preexisting cardiovascular disease. Evaluate and treat underlying causes prior to initiating therapy. Treat priapism immediately. Patient must not adjust dose on own. Reevaluate every 3 months. Significant corpora cavernosa venous leakage. Monitor for signs of penile fibrosis. Discontinue if penile angulation, cavernosal fibrosis, or Peyronie's disease develops. Risk of needle breakage; use proper handling and injection techniques.
Concomitant vasoactive agents: not recommended. Caution with anticoagulants.
Penile pain, prolonged erection, priapism, penile fibrosis, inj site hematoma or ecchymosis, prostatic disorder, penile rash or edema, other local effects, upper respiratory infection, hypertension, headache, increased risk of blood-borne diseases, others.
Vials—6; Caverject Impulse 10mcg, 20mcg—2 (dual chamber syringe systems + supplies)
Endocrinology Advisor Articles
- Higher BUN May Increase Risk for Incident Diabetes
- Efficacy of Novel GLP-1 Receptor Agonist Drug Device Examined
- Takeout Food May Increase Adverse Health Consequences in Children
- Nonhormonal Options Available for Menopause Symptom Relief
- Plasma Volume Changes Mediate Risk of CV Mortality With Empagliflozin
- New Consensus Recommendations on Use of Continuous Glucose Monitoring
- Does Genetic Susceptibility Lead to Late-Onset Type 1 Diabetes?
- Clinical Outcomes in T2D: Low-Carbohydrate vs Calorie-Restricted Diet
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Text Message-Delivered Interventions Effective for Weight Management
- Effect of Intra-Articular Depot Betamethasone on Insulin Resistance in T2D
- Gastric Bypass vs Sleeve Gastrectomy Outcomes in Morbid Obesity
- Acute Kidney Injury Increases Risk for Postdischarge Hypoglycemia in Diabetes
- Novel Deep Learning System May Help Identify Diabetic Retinopathy
- Trends in CVD, Risk Factors, and Medications in Children With T1D